Genmab — September 2019
-
Har vist ikke været omtalt: A Study of Lazertinib as Monotherapy or in Combination With JNJ-61186372 in Japanese Participants With Advanced Non-small Cell Lung Cancer. https://clinicaltrials.gov/ct2/show/NCT04077463?term=jnj+bispecific&rank=2
-
‘Yuhan’s Lazertinib promising as 1st-line therapy for NSCLC’
Expectations are rising for Lazertinib, an investigational drug that Yuhan Corp. licensed out to Janssen for the treatment of non-small cell lung cancer (NSCLC), an analyst said. Meritz Securities said in a report on Monday that the market prospect for Lazertinib continued to rise even after the meeting of the American Society of Clinical Oncology (ASCO). The brokerage advised investors to “buy
KBR (www.koreabiomed.com)
-
-
Handelsbanken sænkede anbefalingen på Zealand Pharma til Sælg for ikke så længe siden. Nu fortryder de og hæver til Hold
-
Banken skriver: Vores tidligere salgsanbefaling byggede på, at prisfastsættelsen var for anstrengt. Derudover vurderede vi, at selskabet
potentielt ville se sig nødsaget til at foretage en emission for
at få penge i kassen, som følge af udsigterne til højere omkostninger og en stigende kommerciel risiko. -
o. I mellemtiden har
Zealand Pharma modtaget en milepælsbetaling på omkring
149 mio. kr., mens man har udstedt 4 mio. nye aktier til en storaktionær for en samlet værdi på omkring 560 mio. kr
Så vi har 200-300 point tilbage hvis shorterne skal have lukket de sidste 2.66%
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind